OBJECTIVE: To determine the prognostic implication of exercise and dipyridamole-induced transient left ventricular cavitary dilation (TLVD). DESIGN: TLVD was observed and a follow-up obtained in 61 patients after exercise and in 62 patients following dipyridamole infusion. PATIENTS: There was no statistical difference between groups in terms of sex, history of hypertension, diabetes, renal failure, previous myocardial infarction, severity of angina syndrome, congestive heart failure, resting electrocardiographic (ECG) abnormalities, clinical or ECG signs of ischemia during stress, number of reversible perfusion defects on thallium images or duration of follow-up (21 months). RESULTS: Dipyridamole patients were slightly older (64 versus 57 years) and displayed more thallium redistribution (P = 0.002). After a mean follow-up of 21 months, both fatal and nonfatal (myocardial infarction or cardiac death) cardiac events were more frequent in the dipyridamole group (50% versus 9%, P = 0.0001). CONCLUSIONS: Patients with dipyridamole-induced TLVD are at greater risk than those with exercise-induced TLVD at the authors' institution.
OBJECTIVE: To determine the prognostic implication of exercise and dipyridamole-induced transient left ventricular cavitary dilation (TLVD). DESIGN: TLVD was observed and a follow-up obtained in 61 patients after exercise and in 62 patients following dipyridamole infusion. PATIENTS: There was no statistical difference between groups in terms of sex, history of hypertension, diabetes, renal failure, previous myocardial infarction, severity of angina syndrome, congestive heart failure, resting electrocardiographic (ECG) abnormalities, clinical or ECG signs of ischemia during stress, number of reversible perfusion defects on thallium images or duration of follow-up (21 months). RESULTS:Dipyridamolepatients were slightly older (64 versus 57 years) and displayed more thallium redistribution (P = 0.002). After a mean follow-up of 21 months, both fatal and nonfatal (myocardial infarction or cardiac death) cardiac events were more frequent in the dipyridamole group (50% versus 9%, P = 0.0001). CONCLUSIONS:Patients with dipyridamole-induced TLVD are at greater risk than those with exercise-induced TLVD at the authors' institution.
Authors: Yuan Xu; Reza Arsanjani; Morgan Clond; Mark Hyun; Mark Lemley; Mathews Fish; Guido Germano; Daniel S Berman; Piotr J Slomka Journal: J Nucl Cardiol Date: 2012-03-08 Impact factor: 5.952
Authors: Carolina Valdiviezo; Apurva A Motivala; Rory Hachamovitch; Murthy Chamarthy; Pablo C Navarro; Robert J Ostfeld; Mimi Kim; Mark I Travin Journal: J Nucl Cardiol Date: 2011-02-15 Impact factor: 5.952
Authors: Manolo Rubio; Andre Dias; Nikoloz Koshkelashvili; Jose N Codolosa; Mauricio Jalife-Bucay; Mary Rodriguez-Ziccardi; Aman M Amanullah Journal: World J Nucl Med Date: 2017 Jul-Sep